|
January 2014 Vol. 3 Issue
1
Other viewing option
Abstract
•
Full
text
•Reprint
(PDF) (180 KB)
Search Pubmed for articles by:
Nour BYM
Saeed OK
Other links:
PubMed Citation
Related articles in PubMed
|
|
Global Advanced Research Journal
of Medicine and Medical Sciences (GARJMMS) ISSN: 2315-5159
January 2014 Vol. 3(1), pp.
001-007
Copyright © 2014 Global Advanced
Research Journals
Full Length Research Paper
|
Efficacy and safety of
artemisinin – naphthoquine (ARCO®) in the treatment
of uncomplicated Plasmodium falciparum among
Sudanese adults
Bakri Y.M. Nour1,2*,
Naser Mahmoud M. Hamed2, Ali Babekir
Habour3, Abd Alla Abd Elkariem1,3,
Ahmed A. Mohamadani2,3 and Osman K Saeed1,4
1Blue
Nile National Institute for Communicable Diseases,
University of Gezira, Wad Medani, Sudan
2Faculty
of Medical Laboratory Sciences, University of Gezira,
Wad Medani, Sudan
3Faculty
of Medicine, University of Gezira, Wad Medani, Sudan
4Wad
Medani College for Medical Sciences and Technology,
Wad Medani, Sudan
*Corresponding
Author E-mail:
saeedosman82@yahoo.com
Accepted 17 December, 2013
|
|
Abstract |
|
Although artemisinin
combined therapies (ACTs) offer great hope for
Africa in controlling malaria, the ideal combination
regimen remains uncertain. ARCO is a single dose
treatment and proven to be efficacious, so this
study aimed to assess the safety and efficacy of
this
new generation ACT
in the treatment of uncomplicated Plasmodium
falciparum among Sudanese adults.
From November 2006
to March 2008, the efficacy and safety of
Artemisinin + Naphthoquine (ARCO)
in the treatment of uncomplicated Plasmodium
falciparum was investigated in Eastern
and Central of Sudan.
129 patients were enrolled
in this study, and were treated with ARCO. All
patients were followed up for 28 days according to
the WHO-in vivo protocol-2003.
The results obtained by ARCO study revealed that the
fever clearance time (FCT)
was (12.0 +/- 4.8 hours) and parasite clearance time
(PCT) was (34.8+/-12.6
hours), Overall clinical and parasitological outcome
showed that adequate clinical and parasitological
response (ACPR) was 120/122 (98.4%), early treatment
failure (ETF) was 0/122 (0%) and late clinical and
parasitological failure (LCPF) was 2/122 (1.6) and
no Gametogenesis was observed during the
follow-up days. ARCO proved to be an effective ACT,
was very safe and well tolerated, no adverse
reaction detected -There was no new events and no
adverse effects on bone marrow
Keywords:
Sudan, malaria treatment, ACT, ARCO.
|
| |
|
